Introduction
• L32: 'Prostate cancer is a leading cause of cancer' does not make sense • It would be useful to include some contextual introductory information, for example, incidence and mortality trends of prostate cancer amongst Portuguese men, is PSA screening common or particularly problematic in this population, what information is currently available to Portuguese-speaking men and their health care providers, and how it is delivered? • Why was the Making the best choice DA selected as the best DA to adapt? Please add 1-2 sentence explanation. (incl KT involvement); how are the print and web versions related?
Methods & Analysis • L24: suggest brief explanation of the 'stakeholder-based approach' and the 'additional steps' taken ('based in another document' -describe) as an introduction to the five-steps that are then outlined • What specifically is involved in 'reviewing' the original DA and associated data? Will the web-based and print versions be reviewed in the same way? Please provide more detail. •
Step 2: is the early review described of the US-DA or draft translated DA? This step is unclear. • L53: if possible, it would be useful to include an example of a culturally or technically inappropriate recommendation • Please provide references to the relevant evidence; was a review conducted?
•
Step 3: please explain further what the quality check involves and whether performed on both translations • Participants: please clarify whether men who have had a PSA screening test in the past will be included • L43: do the men choose whether they participate in an interview or focus group? (are the men who participate in the focus groups different to those interviewed?) Please provide more detail • Please provide an interview schedule or example questions • Interviews L9: please include who it is that men are going through the DA with • FG: I'm unclear what is the purpose of the focus groups so more explanation would be useful in this section. Why have the authors decided to use both interviews and focus groups? • FG: What is the background of the moderator? Please include. • L39: unclear how headphones in a FG setting will workcould DA be shown on a screen to the group to encourage group interaction and discussion? (what are participants responding to on the screen?) •
If the DA will be improved after each interview, does that mean that all men don't ever see the same DA? Rationale for this method of revising the DA between every interview needs to be provided. • Please explain the difference between the planned thematic categoric analysis and the content analysis (p8)
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name: Axel Semjonow Institution and Country: Prostate Center University Münster, Germany Please leave your comments for the authors below The manuscript is concerned with a clinically relevant subject, announcing a study on evaluating a decision aid which will be translated, adapted and transferred from the USA to Portugal. I only want to raise some minor Points which could be adressed in a revision: 1. "screening" vs. "early detection should be used consistently through out the paper. As far as I know, there is no Population based PSA Screening in Portugal, so I would prefer "early detection".
Indeed, there is no population-based screening in Portugal and early detection is the adequate term to be rigorous. We will include this sentences in the introduction to clarify the difference between the two terms and its use throughout the text:
"Screening can be defined as the use of simple tests across a healthy population to identify those individuals who have a disease, but do not yet have symptoms [WHO] . Early detection refers to applying tests to asymptomatic individuals who consult a health professional. Throughout the text the term "screening" will be used to refer both to systematic screening and early detection. " 2. why are participants accepted for the age group of 50 -69 years? There is only one study proving a mortality reduction (ERSPC). This proof is only available for men aged 55-69 years. Where does the evidence in the DA come from to lower to 50 years?
We will include only 55-69 aged men, in accordance to the core group of ERSPC.
Why is a Family history of prostate cancer an exclusion criterion?
We agree there is not a good rationale for excluding these men. Indeed, they also benefit from using decision aids to make a decision regarding early detection. 4. I would recommend to ask participants BEFORE and AFTER exposure to the DA about their choice to participate or not participate in PSA-based early detection.
We understand this suggestion as another possibility of enriching our work. However, we would prefer not to do it at this point, since we are not trying to assess the impact of the decision aid in terms of decision quality outcomes. Through this qualitative methodology we aim at understanding men's views on the translated decision aid to better adapt it to Portuguese population. Please leave your comments for the authors below The authors have done a very good of describing the procedures they will use to create Portuguese versions of a decision aid for men deciding whether or not to get PSA testing for prostate cancer. All the steps seem well thought out and appropriate.
"analysys
Reviewer: 4 Reviewer Name: Dr Kristen Pickles Institution and Country: The University of Sydney Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below Thank you for the opportunity to review this protocol paper describing the authors' proposal to translate a US-developed patient decision aid supporting men's prostate cancer screening choice from English to Portuguese. I read the process outlined with interest and have just a few comments below, mainly requesting more detailed explanation of the process throughout.
Abstract
• Methods and analysis L21: 'after an early review'.. Please specify what was reviewed.
We will add the texto below to the methods section:
This early review was conducted by the process coordinator and a linguistic expert and aimed at removing culturally and technically inappropriate recommendations. Examples include: 1) replacing the photos in the original decision aid with photos of Portuguese men; 2) replacing references to the American Societies/Associations' recommendations (with exception to USPSFT) by the recommendations by the Portuguese Directorate-General for Health; 3) replacing American epidemiological data by Portuguese epidemiological data; 4) in a testimony there was this sentence: "That's why I signed up for a free prostate screening program.", this needed adaptation since it does not apply in the Portuguese healthcare service reality.
• Suggest that the authors make it clear that they are not 'testing the decision aid' as such in terms of its effectiveness for decision support, rather checking the translation Indeed, with this qualitative design we aim at understanding men's views on the translated decision aid to better adapt it to Portuguese population. We added this sentence to make it more clear: Our main goal is to understand men's views on the translated decision aid to better adapt it to the Portuguese population, thus improving the decision aid through an iterative process based on data collection and parallel data analysis. In the methods section of the abstract we have therefore eliminated the term "test" and added: "We will further improve the decision aid through an iterative process of data collection, data analysis and decision aid review."
• Please specify the location of the local community from which the men will be recruited
We added the information that data will be collected in urban and suburban communities in Oporto district.
Introduction
• L32: 'Prostate cancer is a leading cause of cancer' does not make sense Corrected: "Prostate cancer is the most common cancer among men worldwide (1.6 million cases) and the seventh leading cause of male cancer death, with a total of 366000 deaths [1] . (notereference: Global Burden of Disease Collaboration 2017)
• It would be useful to include some contextual introductory information, for example, incidence and mortality trends of prostate cancer amongst Portuguese men, is PSA screening common or particularly problematic in this population, what information is currently available to Portuguesespeaking men and their health care providers, and how it is delivered?
We rearranged the introduction in order to include the new suggested data. "In Portugal, there are 90,5 new prostate cancer cases yearly per 100,000 inhabitants, making it the leading male cancer in terms of incidence. The adjusted mortality rate in 2014 was 20,3/100,000 with an absolute number of 1787 deaths from prostate cancer The recommendations physicians should follow are from the Directorate-General for Health (DGS), as stated in the text. As far as we are aware, there is no publicly available data on PSA prescription in Portugal. There is data that suggests that most Portuguese men consider they should be screened for prostate cancer, and we have added the sentence: "A 2013 population-based cross-sectional study showed that 67,3% of the Portuguese adult men consider that PSA test should be performed. [16] ."
• Why was the Making the best choice DA selected as the best DA to adapt? Please add 1-2 sentence explanation. (incl KT involvement); how are the print and web versions related?
We added this explanation to the methods section:
We searched for prostate cancer screening decision aids in the A to Z inventory from the Ottawa Hospital Research Institute (https://decisionaid.ohri.ca/). The first author critically appraised the decision aids using IPDAS criteria. Thereafter, we identified those which fulfilled most of the quality criteria. Of those, we selected the "Making the Best Choice" decision aid because it was presented in two different formats (paper and web). "Making the best choice" is an English language prostate cancer screening decision aid which has been rigorously developed [25] and extensively tested [26-30] by a workgroup from Georgetown University (USA). We sought permission to translate and adapt the decision aid to the Portuguese population. KT, who was the principal investigator of the original decision aid is a co-investigator in this project. Briefly, the print and web version of the decision aid share identical content and have an eighth-grade reading level. The informational sections include introductory material about the prostate gland; a description of screening tests and possible results; information about treatment options, risks, and adverse effects; a review of prostate cancer risk factors and encouragement to discuss screening with a physician (but without instructions to make an immediate appointment); a 10-item values clarification tool; and resources for more information (references and a glossary). Additionally, the web decision aid includes pop-up definitions of 77 terms, video testimonials, an interactive values clarification tool, and figures and animations. The decision aid has been found to improve prostate cancer knowledge and to reduce decisional conflict, with these changes remaining significant at the 13 months follow-up. Satisfaction was also higher for both formats in comparison with usual care; screening rates did not differ significantly among groups [27] .
Methods & Analysis • L24: suggest brief explanation of the 'stakeholder-based approach' and the 'additional steps' taken ('based in another document' -describe) as an introduction to the five-steps that are then outlined We tried to improve the explanation as suggested:
We decided to follow the European Center for Disease Prevention and Control's (ECDC) five-step, stakeholder-based approach to adapting health communication materials [19] . This approach was developed, tested and evaluated through a series of ECDC projects with public health practitioners, agencies and associations in seven European Union countries [29] . It involves active engagement of patients, clinicians and researchers to ensure quality, comprehension, contextual and cultural appropriateness and applicability of any the adapted decision aids.
• What specifically is involved in 'reviewing' the original DA and associated data? Will the web-based and print versions be reviewed in the same way? Please provide more detail.
That first step corresponds simply to the appraisal of the decision aid, its first readings to get familiar with and identifying its main features. As stated in the text, "(…) in order to identify the core elements of the decision aid namely, those concerning format and design features, structure, rationale and contents.".
•
Step 2: is the early review described of the US-DA or draft translated DA? This step is unclear.
The early review will be done before translation: "Before starting the translation, the decision aid will be reviewed by the process coordinator and also by a linguistic expert."
• L53: if possible, it would be useful to include an example of a culturally or technically inappropriate recommendation As stated earlier, we added to the text in the methods section: This early review was conducted by the process coordinator and a linguistic expert and aimed at removing culturally and technically inappropriate recommendations. Examples of changes done after this early review include: 1) replacing the photos in the original decision aid with photos of Portuguese men; 2) replacing references to the American Societies/Associations' recommendations (with exception to USPSFT) by the recommendations by the Portuguese Directorate-General for Health; 3) replacing American epidemiological data by Portuguese epidemiological data; 4) in a testimony there was this sentence: "That's why I signed up for a free prostate screening program.", this needed adaptation since it does not apply in the Portuguese healthcare service reality.
• Please provide references to the relevant evidence; was a review conducted?
To update the decision aid we conducted a review of the most robust and recente evidence in the field, using the following references, which are stated in the references section of the decision aid; should we also include them in this protocol?: Andriole GL, Crawford ED, Grubb RL 3rd, et al; PLCO Project Team. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up. J Natl Cancer 2012; 104:125-32. PMID: 22228146. Direcção Geral de Saúde (2017) . Prescrição e Determinação do Antigénio Específico da Próstata -PSA. Norma de Orientação Clínica 060/2011. Direcção Geral de Saúde. Programa Nacional para as Doenças Oncológicas. Portugal -Doenças Oncológicas em Números -2015. Fay, M.P., Pfeiffer, R., Cronin, K.A., Le, C. and Feuer, E.J. (2003) . Age-conditional probablities of developing cancer. Statistics in Medicine, 22 (11) The reference to the quality check step was indeed misleading. We have changed the term "quality check" simply for the backtranslation step (including revision of the backtranslated version). According to CDC Translation is not enough document "Quality check. This is a key step to ensure that no misunderstandings or mistranslations have occurred during the transla¬tion process. (…) this step can be performed in different ways. This step is very important as it will ensure that end-users receive a conceptually accurate local language version of document. Conceptual errors that go unnoticed can undermine the accuracy and utility of the final product. Such quality checks are the only way in which sponsoring organisations, whose staff may not understand the language of the adapted document, can ensure that concepts have been accurately translated."
• Participants: please clarify whether men who have had a PSA screening test in the past will be included Yes, it is not an exclusion criterion and we clarified this in the manuscript. In fact, we think that men should be included, because albeit having done a PSA test in the past they may be again faced with the decision whether to do again or not the test, they may not have made an informed choice in the past, so they may give us interesting feedback concerning the decision aid.
• L43: do the men choose whether they participate in an interview or focus group? (are the men who participate in the focus groups different to those interviewed?) Please provide more detail After reflecting on your comments, we decided to abandon focus groups (please refer to the explanation below).
• Please provide an interview schedule or example questions
An interview guide will be provided as supplementary material.
• Interviews L9: please include who it is that men are going through the DA with The interviews will be conducted by three family medicine residents (who are not involved in participants' health care) in accordance with an interview guide.
• FG: I'm unclear what is the purpose of the focus groups so more explanation would be useful in this section. Why have the authors decided to use both interviews and focus groups?
After discussion within our research group, we decided that the focus groups would not add much to the information collected through individual cognitive interviews. So we decided to abandon the focus groups.
• FG: What is the background of the moderator? Please include.
We decided to abandon focus groups.
• L39: unclear how headphones in a FG setting will work -could DA be shown on a screen to the group to encourage group interaction and discussion? (what are participants responding to on the screen?)
• If the DA will be improved after each interview, does that mean that all men don't ever see the same DA? Rationale for this method of revising the DA between every interview needs to be provided.
Our description is not accurate. We plan to do 10 interviews, analyse them, and update the decision aid according to the interviewees' feedback. Thereafter, we plan to do a last round of 5 interviews with the corrected decision aid in
